Tag Archives: uthr

4 Top-Rated Drugmakers Reporting Earnings This Week

This week will bring first-quarter earnings reports from four top-rated large-cap drug stocks, and each is expected to report strong growth. On Tuesday before the open, United Therapeutics (UTHR) is expected to report revenue of $353.5 million, up 22% from the year-earlier quarter, according to Thomson Reuters. Earnings are expected to climb 44% to $3.14 a share, though given how much stock-based compensation is included in that figure, analysts

United Therapeutics Wins FDA Nod, Priority Voucher

Biotech United Therapeutics (UTHR) received Food and Drug Administration approval for its first cancer drug Tuesday and was also awarded a priority-review voucher, which could turn out to be just as lucrative. The agency approved Unituxin, a monoclonal antibody that treats an ultra-rare childhood cancer called neuroblastoma. With only about 650 new cases a year, consensus estimates expect only $73 million in annual sales from the drug by 2019. To

Jazz Pharma Tops Q4 Views, But Outlook Disappoints

Jazz Pharmaceuticals shares fell late Tuesday after the drugmaker topped fourth-quarter estimates but guided 2015 revenue and profit below views. That followed United Therapeutics (UTHR), which also logged better-than-expected Q4 results. Jazz (JAZZ) earned $2.44 a share excluding a variety of items, up 42% a year earlier and 14 cents above consensus estimates. Revenue gained 39% to $328.1 million vs. views for $319.1 million.